secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2022-03-30T23:59:59+00:00
Accession:  0001104659-22-039716
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE reports positive preclinical RA data for pan-BET inhibitor VYN201; on track for H2 2022 Ph1
--------------------------------------------------------------------------------

- VYN201 intra-articular injection showed statistically significant inhibition of paw thickening at 1 and 10 mg/kg (p<0.01).
- At 1 mg/kg, paw thickness reduced 26.8% vs untreated; at 10 mg/kg, reduced 37.6%.
- Arthritis scores at 1 and 10 mg/kg were near normal (0.57 and 0.67), reductions of 76.5% and 79.9%.
- VYN201 numerically superior to intra-articular dexamethasone in both endpoints.
- Company confirms timeline to initiate first-in-human trial for VYN201 in second half of 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922039716/0001104659-22-039716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922039716/tm228420d6_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-039716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer